Tokamak: British Patient Capital Invests £8m in Fusion Energy Innovation
Deal News | Nov 20, 2024 | British Patient Capital
British Patient Capital has invested £8 million into Tokamak Energy as part of a significant $125 million financing round. This funding round, co-led by East X Ventures and Lingotto Investment Management, includes investments from Furukawa Electric Company, the BW Group, and Sabanci Climate Ventures. The funding aims to accelerate the commercialisation of fusion energy and the development of Tokamak Energy's high-temperature superconducting technology, TE Magnetics. Originally a spin-out from the UK Atomic Energy Authority, Tokamak Energy has raised $335 million since its formation in 2009, with contributions from both private investors and the UK and U.S. governments. The investment from British Patient Capital is sourced from the £425 million Future Fund: Breakthrough programme, supporting rapid growth to meet demands in the fusion energy market and other industries. This will also support advancements in Tokamak Energy’s fusion pilot plant and its groundbreaking ST40 tokamak experiments near Oxford, pursuing innovations that aim to make fusion energy a viable and limitless resource for global energy needs.
Sectors
- Energy
- Finance
- Technology
Geography
- United Kingdom – Tokamak Energy is based in the UK, and British Patient Capital, a UK-based investment, supports its efforts. Additionally, the UK Atomic Energy Authority is part of Tokamak Energy’s history.
- United States – The article mentions U.S. government funding and a U.S.-based investor, Sabanci Climate Ventures, indicating a geographical relevance to the United States.
Industry
- Energy – The article focuses on fusion energy, specifically the development of advanced technologies aimed at commercialising this energy source, making the energy sector highly relevant.
- Finance – The involvement of British Patient Capital and other investors in a significant financing round places the financial sector at the core of the article's focus.
- Technology – Tokamak Energy's work on high temperature superconducting technology, TE Magnetics, and advanced fusion technology positions the company firmly within the technology sector.
Financials
- £8 million – The investment amount made by British Patient Capital into Tokamak Energy.
- $125 million – The total amount of the financing round for Tokamak Energy.
- $335 million – The total amount Tokamak Energy has raised since its formation.
- $275 million – The amount raised from private investors by Tokamak Energy since inception.
- $60 million – The amount of government funding received by Tokamak Energy from both the UK and U.S. governments.
- £425 million – The total fund size of the Future Fund: Breakthrough programme from which the British Patient Capital's investment was made.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Tokamak Energy | Target Company | Company | A company developing fusion energy technologies, focusing on high temperature superconducting solutions and fusion pilot plants. |
| British Patient Capital | Investor | Company | A UK-based investment firm that participated in the funding round to support Tokamak Energy. |
| East X Ventures | Co-lead Investor | Company | A co-lead investor in the $125 million financing round for Tokamak Energy. |
| Lingotto Investment Management | Co-lead Investor | Company | Another co-lead investor in the Tokamak Energy financing round. |
| Furukawa Electric Company | Investor | Company | A new investor involved in the Tokamak Energy funding round. |
| BW Group | Investor | Company | A global maritime company participating as a new investor in the financing round. |
| Sabanci Climate Ventures | Investor | Company | A U.S.-based investor participating in the financing round. |